Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis |
| |
| Authors: | Trenque T Simon N Villena I Chemla C Quereux C Leroux B Jaussaud R Rémy G Dupouy D Millart H Pinon J-M Urien S |
| |
| Affiliation: | Laboratoire de Pharmacologie-Toxicologie, CHU, Reims, France. ttrenque@chu-reims.fr |
| |
| Abstract: | AIMS: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. METHODS: Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg). Plasma concentrations, available from a therapeutic drug monitoring database, were determined by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model. RESULTS: Eighty-nine children, aged 1 week to 14 years and weighing 2.9-59 kg, were available for evaluation. Both PYR and SDX concentration-time profiles were best described by a one-compartment open model. Volume of plasma distribution (V) and clearance (CL) were significantly related to body weight (BW) using an allometric function. Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX. For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX. CONCLUSION: This study indicated that body weight influences PYR and SDX pharmacokinetics in children. To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate. |
| |
| Keywords: | children congenital toxoplasmosis pharmacokinetics population pyrimethamine sulfadoxine |
| 本文献已被 PubMed 等数据库收录！ |
|
